JC02 Rec'd PCT/PTC 21 APR 2005

ORM PTO-1390 (Modified) U.S. PATENT AND TRADEMARK OFFICE; U.S. DEPARTMENT OF COMMERCE REV. 12-2004) ATTORNEY'S DOCKET NUMBER TRANSMITTAL LETTER TO THE UNITED STATES P33127USw U.S. APPLICATION NO. (If known, see 37 CFR 1.5) DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A SUBMISSION UNDER 35 U.S.C. 371 INTERNATIONAL APPLICATION NO. INTERNATIONAL FILING DATE PRIORITY DATE CLAIMED 22 October 2002 20 October 2003 PCT/EP2003/01164 a TITLE OF INVENTION Aryloxyalkylamine Derivatives as H3 Receptor Ligands APPLICANT(S) FOR DO/EO/US Desmond John BEST, Gordon BRUTON, Thomas Daniel HEIGHTMAN, Barry Sidney ORLEK Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information: \boxtimes This is a FIRST submission of items concerning a submission under 35 U.S.C. 371. This is a SECOND or SUBSEQUENT submission of items concerning a submission under 35 U.S.C. 371. 2. This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), 3. (9) and (24) indicated below. The US has been elected (Article 31). 4. A copy of the International Application as filed (35 U.S.C. 371 (c)(2)) is attached hereto (required only if not communicated by the International Bureau). has been communicated by the International Bureau. b. 🛛 is not required, as the application was filed in the United States Receiving Office (RO/US). An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). a. 🗆 is attached hereto. has been previously submitted under 35 U.S.C. 154(d)(4). Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3)) Ø 7. are attached hereto (required only if not communicated by the International Bureau). а. П have been communicated by the International Bureau. b. 🗆 have not been made; however, the time limit for making such amendments has NOT expired. c. 🗆 d. 🛛 have not been made and will not be made. An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 8. \boxtimes An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)). 9. An English language translation of the annexes to the International Preliminary Examination Report under PCT 10. Article 36 (35 U.S.C. 371 (c)(5)). A copy of the International Preliminary Examination Report (PCT/IPEA/409). \boxtimes 11. \boxtimes A copy of the International Search Report (PCT/ISA/210). 12. Items 13 to 23 below concern document(s) or information included: 13. \bowtie An Information Disclosure Statement under 37 CFR 1.97 and 1.98. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 14. 15. \bowtie A FIRST preliminary amendment. П A SECOND or SUBSEQUENT preliminary amendment. 16. 17. A substitute specification. 18. A power of attorney and/or change of address letter. 19. A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821 - 1.825. 20. A second copy of the published International Application under 35 U.S.C. 154(d)(4). A second copy of the English language translation of the International Application under 35 U.S.C. 154(d)(4). \boxtimes 22. Express Mail Label No. EV332065624US Ø 23. Other items or information: Copy of PCT Publication coverpage; Copy of PCT Request

JC12 Rec'd PCT/F. 2 1 APR 2005

PTO-1390 (Rev. 12-2004)

Approved for use through 3/31/2007. OMB 0651-0021

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Onder the Caperine								
U.S. APPLICATION NO (if known, see 37 CFR 1.5) INTERNATIONAL APPLICATION NO.						ATTORNEY'S DOCKET NUMBER		
10/532314 PCT/EP2003/01164						P33127		
24. The following fees are submitted:						Applicant use	Office use	
☐ a) Basic national fee						\$ \$300.00)	
B b) Examination fee						\$ \$200.00		
区 c) Search fee						\$ \$400.00	0	
TOTAL OF ABOVE CALCULATIONS = \$1000.00						\$ \$900.00)	
Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing or computer program listing filed in an electronic medium). The fee is \$250 for each additional 50 sheets of paper or fraction thereof.								
Total Sheets	Extra Sheets	Extra Sheets Number of each additional 50 or fraction thereof (round up to a whole			RATE			
57 - 100 =			0		× \$250.00	\$ \$0.00		
Surcharge of \$130.00 for furnishing the oath or declaration later than months from the earliest claimed priority date (37 CFR 1.492(e)).						\$		
CLAIMS	NUMBER F		NUMBER EXTRA		RATE			
Total claims	4	- 20 =	0	x	\$50.00	\$ \$0.00	<u> </u>	
Independent cla	ims 0	- 3=	0	х	\$200.00	\$ \$0.00		
MULTIPLE DEPENDENT CLAIMS (if applicable) ☐ + \$360.00						\$ \$0.00		
TOTAL OF ABOVE CALCULATIONS =						\$ \$900.00		
Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.						\$ \$0.00		
SUBTOTAL =						\$ \$900.00		
Processing fee of \$130.00 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(f)).						\$ \$0.00		
						\$ \$900.00		
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40 per property +						\$ \$0.00		
TOTAL FEES ENCLOSED =						\$ \$900.00		
Amount to be refunded:							\$	
Amount to be charged:							\$	
a. A check in the amount of \$ to cover the above fees is enclosed.								
	charge my Deposit		o. <u>07-1392</u> ir	n the	amount of	\$900.00 to cov	er the above fees.	
	The Director is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No A duplicate copy of this sheet is enclosed.							
	d. Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.							
NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the International Application to pending status.								
SEND ALL CORRESPONDENCE TO:						7 1 2 4-2	1-05	
23347 SIGNATURE Lames P. I								
James P. F						иек		
39,009								
						ION NUMBER		
		TON NUMBER						

JC12 Rec'd PC G BY "EXPRESS MAIL" (37 CFR CERTIFICATE OF MA Applicant(s): BEST et al. P33127USw Examiner Customer No. **Group Art Unit** Application No. Filing Date 23347 Aryloxyalkylamine Derivatives as H3 Receptor Ligands Invention: I hereby certify that the following correspondence: Submission under 35 USC 371, Declaration, Preliminary Amendment, Int'l Preliminary Examination Report, Int'l Search Report, IDS-1449, 13 references, Copy of PCT publication coverpage, Copy of PCT Request (Identify type of correspondence) is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

April 21, 2005

Patty Wilson
(Typed or Printed Name of Person Mailing Correspondence)

(Signature of Person Mailing Correspondence)

EV3320L5L24US

("Express Mail" Mailing Label Number)

Note: Each paper must have its own certificate of mailing.